| Literature DB >> 26784169 |
Jiaming Su1, Fei Wang2, Yong Cai3,4,5, Jingji Jin6,7,8.
Abstract
Changes in chromatin structure and heritably regulating the gene expression by epigenetic mechanisms, such as histone post-translational modification, are involved in most cellular biological processes. Thus, abnormal regulation of epigenetics is implicated in the occurrence of various diseases, including cancer. Human MOF (males absent on the first) is a member of the MYST (Moz-Ybf2/Sas3-Sas2-Tip60) family of histone acetyltransferases (HATs). As a catalytic subunit, MOF can form at least two distinct multiprotein complexes (MSL and NSL) in human cells. Both complexes can acetylate histone H4 at lysine 16 (H4K16); however, the NSL complex possesses broader substrate specificity and can also acetylate histone H4 at lysines 5 and 8 (H4K5 and H4K8), suggesting the complexity of the intracellular functions of MOF. Silencing of MOF in cells leads to genomic instability, inactivation of gene transcription, defective DNA damage repair and early embryonic lethality. Unbalanced MOF expression and its corresponding acetylation of H4K16 have been found in certain primary cancer tissues, including breast cancer, medulloblastoma, ovarian cancer, renal cell carcinoma, colorectal carcinoma, gastric cancer, as well as non-small cell lung cancer. In this review, we provide a brief overview of MOF and its corresponding histone acetylation, introduce recent research findings that link MOF functions to tumorigenesis and speculate on the potential role that may be relevant to tumorigenic pathways.Entities:
Keywords: H4K16ac; MOF; MYST; histone acetyltransferase; tumorigenesis
Mesh:
Substances:
Year: 2016 PMID: 26784169 PMCID: PMC4730341 DOI: 10.3390/ijms17010099
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Functional domains of the MOF protein.
Figure 2The NSL complex shares subunits with other chromatin-regulating complexes. hMLL, human mixed-lineage leukemia; SET, set-domain containing; INO80, INOsitol-requiring 80; NFRKB, nuclear factor related to kappaB protein; YY1, Yin Yang 1; GCN, general control of amino acid synthesis; MBIP, MAP3K12 binding inhibitory protein 1; ADA, transcriptional adaptor; STAF, YEATS2, YEATS domain-containing 2; NC2β, down-regulator of transcription 1; CSRP2BP, CSRP2 binding protein; RBBP, retinoblastoma binding protein; DYP30, protein dpy-30 homolog; PTIP, PAX interacting (with transcription-activation domain) protein 1; WDR, WD repeat domain.
Figure 3Functional regulation of MOF in cells. TMS, Target of methylation-mediated silencing, also known as ASC. Green: non-histone proteins are acetylated by MOF; Purple: pathways associated with MOF-mediated H4K16ac; Brown: functions associated with MOF-containing complexes; Gray: MOF is implicated in DNA damage repair.
Changes in H4K16 acetylation and histone modifiers occurring in different cancers.
| Cancer Type | Samples | Method | Modifiers | Results | H4K16ac | Reference |
|---|---|---|---|---|---|---|
| Tissue (98) | Gene profiling | MOF | Downregulated (40%) | ---- | [ | |
| Tissue (298) | IHC | MOF | Reduced or undetectable (18%) | H4K16ac ↓ | [ | |
| Cell lines | RT-PCR, WB | MOF/SUV420H2 | Regulate Pol II pausing | ---- | [ | |
| Cell lines | RT-PCR, WB | MOF | Silencing | H4K16ac ↓ | [ | |
| Tissue (47) | RT-qPCR | MOF | Reduced mRNA (74%) | H4K16ac ↓ | [ | |
| Tissue (21) | RT-PCR, WB, IHC | MOF | Reduced mRNA/protein (91%) | H4K16ac ↓ | [ | |
| Tissue (14) | RT-PCR | MOF | mRNA downregulated (79%) | ---- | [ | |
| Tissue (180) | IHC | MOF | Reduced or undetectable (40%) | H4K16ac ↓ | [ | |
| Tissue (16) | RT-qPCR | MOF | mRNA downregulated (94%) | ---- | [ | |
| Tissue (52) | RT-qPCR | MOF | mRNA downregulated (81%) | ---- | [ | |
| Cell lines | RT-qPCR, WB, IF | MOF/HDAC4 | Low MOF/high HDAC4 | H4K16ac ↓ | [ | |
| Tissue (44) | RT-qPCR, IHC | MOF | Reduced mRNA (57%)/protein | H4K16ac ↓ | [ | |
| Tissue (57) | RT-qPCR, WB, IHC | MOF | Reduced mRNA/protein (65%) | H4K16ac ↓ | [ | |
| Tissue (30) | RT-PCR, WB | MOF | Reduced mRNA/protein | H4K16ac ↓ | [ | |
| Tissue (70) | RT-qPCR, WB, IHC | MOF | Reduced mRNA/protein | ---- | [ | |
| Cell lines | RT-qPCR | MOF | Reduced mRNA | ---- | [ | |
| Tissue (43) | IHC | MOF | Increase protein (14/43) | H4K16ac ↑ | [ | |
| Tissue (54) | RT-PCR, IHC | MOF | Increased mRNA/protein (>34) | ---- | [ | |
| Tissue (20) | RT-PCR | MOF | Increased mRNA (50%) | ---- | [ |
RCC: Renal cell carcinoma; NSCLC: non-small cell lung carcinoma; gene profiling: gene expression profiling; IHC: immunohistochemistry; RT-PCR: reverse transcription PCR; qPCR: real-time quantitative PCR; WB: Western blot; IF: Immunofluorescence:, ↓: low level of H4K16ac; ↑: high level of H4K16ac.
Figure 4Schematic diagram of human MOF (hMOF)-related mechanisms in the process of tumorigenesis. MLL, mixed-lineage leukemia.